Institutional shares held 16.3 Million
367K calls
69.2K puts
Total value of holdings $24M
$538K calls
$101K puts
Market Cap $244M
165,875,008 Shares Out.
Institutional ownership 9.84%
# of Institutions 107


Latest Institutional Activity in ATAI

Top Purchases

Q1 2025
Kingswood Wealth Advisors, LLC Shares Held: 70K ($103K)
Q1 2025
Regent Peak Wealth Advisors LLC Shares Held: 20K ($29.4K)
Q1 2025
Wealthcare Advisory Partners LLC Shares Held: 10K ($14.7K)
Q1 2025
Principia Wealth Advisory, LLC Shares Held: 4.27K ($6.27K)
Q4 2024
Ubs Group Ag Shares Held: 1.94M ($2.85M)

Top Sells

Q1 2025
Sg Americas Securities, LLC Shares Held: 27.6K ($40.6K)
Q1 2025
Robertson Stephens Wealth Management, LLC Shares Held: 16.7K ($24.6K)
Q4 2024
Barclays PLC Shares Held: 165K ($243K)
Q4 2024
Royal Bank Of Canada Shares Held: 8.81K ($12.9K)
Q4 2024
Two Sigma Investments, LP Shares Held: 391K ($575K)

About ATAI

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.


Insider Transactions at ATAI

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
13.1M Shares
From 6 Insiders
Open market or private purchase 12.6M shares
Exercise of conversion of derivative security 428K shares
Sell / Disposition
334K Shares
From 6 Insiders
Open market or private sale 334K shares

Track Institutional and Insider Activities on ATAI

Follow ATAI Life Sciences N.V. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATAI shares.

Notify only if
Any

Insider Trading

Get notified when an Atai Life Sciences N.V. insider buys or sells ATAI shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to ATAI Life Sciences N.V.

Track Activities on ATAI